MS Drugs Differ Most on Relapses, Not Disability, Real-World Study Shows

(MedPage Today) -- New multiple sclerosis (MS) patients treated with B-cell-depleting drugs or high-efficacy therapies had lower relapse rates and fewer brain lesions than those treated with oral drugs, but at 2 years, disability outcomes were...